Currently, there are 3.38B common shares owned by the public and among those 3.34B shares have been available to trade.
The company’s stock has a 5-day price change of -2.79% and -20.35% over the past three months. NVO shares are trading 3.49% year to date (YTD), with the 12-month market performance up to 5.80% higher. It has a 12-month low price of $94.73 and touched a high of $148.15 over the same period. NVO has an average intraday trading volume of 4.18 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.79%, -10.95%, and -16.57% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Novo Nordisk ADR (NYSE: NVO) shares accounts for 10.06% of the company’s 3.38B shares outstanding.
It has a market capitalization of $357.41B and a beta (3y monthly) value of 0.41. The stock’s trailing 12-month PE ratio is 34.72, while the earnings-per-share (ttm) stands at $3.08. The company has a PEG of 3.16 and a Quick Ratio of 0.75 with the debt-to-equity ratio at 0.47. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.06% over the week and 1.76% over the month.
Earnings per share for the fiscal year are expected to increase by 21.54%, and 24.61% over the next financial year. EPS should shrink at an annualized rate of 11.00% over the next five years, compared to 16.48% over the past 5-year period.
Looking at the support for the NVO, a number of firms have released research notes about the stock. Goldman stated their Buy rating for the stock in a research note on May 30, 2024, with the firm’s price target at $156. BMO Capital Markets coverage for the Novo Nordisk ADR (NVO) stock in a research note released on April 12, 2024 offered a Outperform rating with a price target of $163. Cantor Fitzgerald on their part issued Overweight rating on December 01, 2023.
